Pub Date : 2025-08-22DOI: 10.1016/s2213-8587(25)00254-2
Naveed Sattar
No Abstract
没有抽象的
{"title":"Rethinking obesity through the lens of genetics, environment and differential life circumstances","authors":"Naveed Sattar","doi":"10.1016/s2213-8587(25)00254-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00254-2","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"18 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144901698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-22DOI: 10.1016/s2213-8587(25)00196-2
Yang He MD, Nianrong Mi MMed, Prof Zhifeng Cheng MD, Prof Haibo Xue MD, Jie Han MMed, Prof Haifang Wang MMed, Huihui Wang MD, Jun Wu PhD, Prof Xiaoguang Shi MD, Shuping Zhao MBBS, Prof Binhong Duan MMed, Prof Yikun Zhu PhD, Prof Yanqin Zhou MBBS, Prof Feng Li MBBS, Xin Wang MMed, Hongwei Ling MMed, Su Wang MMed, Prof Qingju Li MMed, Feifei Jiang MMed, Ming Yang MMed, Shaohui Bing MMed, Qing Zheng MSc, Jing Ning BSc, Mengying Guo BSc, Yue Bu BSc, Lei Guan MMed, Yao Li MSc, Liu Yang M Eng, Wanjun Guo MSc, Hai Pan PhD, Prof Xiaoying Li MD
Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.
{"title":"Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial","authors":"Yang He MD, Nianrong Mi MMed, Prof Zhifeng Cheng MD, Prof Haibo Xue MD, Jie Han MMed, Prof Haifang Wang MMed, Huihui Wang MD, Jun Wu PhD, Prof Xiaoguang Shi MD, Shuping Zhao MBBS, Prof Binhong Duan MMed, Prof Yikun Zhu PhD, Prof Yanqin Zhou MBBS, Prof Feng Li MBBS, Xin Wang MMed, Hongwei Ling MMed, Su Wang MMed, Prof Qingju Li MMed, Feifei Jiang MMed, Ming Yang MMed, Shaohui Bing MMed, Qing Zheng MSc, Jing Ning BSc, Mengying Guo BSc, Yue Bu BSc, Lei Guan MMed, Yao Li MSc, Liu Yang M Eng, Wanjun Guo MSc, Hai Pan PhD, Prof Xiaoying Li MD","doi":"10.1016/s2213-8587(25)00196-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00196-2","url":null,"abstract":"Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus dulaglutide, also a GLP-1 receptor agonist, in patients with type 2 diabetes.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"24 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-22DOI: 10.1016/s2213-8587(25)00219-0
André J Scheen
No Abstract
没有抽象的
{"title":"Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?","authors":"André J Scheen","doi":"10.1016/s2213-8587(25)00219-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00219-0","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"29 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-15DOI: 10.1016/s2213-8587(25)00164-0
Soo Lim, Supawan Buranapin, Xiaolei Bao, María Quiroga, Kyung Hee Park, Jee-Hyun Kang, Anders Rasmussen Rinnov, Arisara Suwanagool
Background
Consistent with WHO recommendations, obesity is defined as BMI ≥25 kg/m2 in many Asian populations because of increased health risks at lower BMIs than in other populations. We aimed to investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2·4 mg versus placebo in an Asian population with BMI ≥25 kg/m2, together with lifestyle interventions.
Methods
STEP 11 was a 44-week, randomised, double-blind, placebo-controlled, phase 3 trial conducted at 12 clinical sites in South Korea and Thailand. Adults (aged ≥18 years in Thailand and ≥19 years in South Korea) with obesity (BMI ≥25 kg/m2) of Asian descent, without diabetes, were randomly assigned 2:1 with a computer-generated sequence and block randomisation to once-weekly subcutaneous semaglutide 2·4 mg or placebo, with a reduced-calorie diet and increased physical activity. Participants, care providers, investigators, and assessors were masked to allocation. Coprimary endpoints, measured in all randomly assigned participants by intention to treat, were percentage bodyweight change and the proportion of participants reaching ≥5% bodyweight reduction. Confirmatory secondary endpoints were the proportion of participants with ≥10% and ≥15% bodyweight reductions and change in waist circumference. Safety was assessed via the assessment of adverse events in all participants who received at least one dose of semaglutide or placebo. This trial was registered at ClinicalTrials.gov (NCT04998136).
Findings
Between Aug 15, 2022, and Nov 20, 2023, 150 participants were randomly assigned (101 to semaglutide 2·4 mg and 49 to placebo). Six (6%) in the semaglutide group and two (4%) in the placebo group discontinued treatment before week 44. 111 (74%) were female and 39 (26%) male, with a mean age of 39 years (SD 11), mean bodyweight of 83·8 kg (18·1), and mean BMI of 31·3 kg/m2 (5·2). At week 44, mean change in bodyweight was −16·0% (SE 0·7) in the semaglutide 2·4 mg group versus −3·1% (0·9) in the placebo group (p<0·0001), and a greater proportion of participants reached bodyweight reductions of ≥5% (96 [96%] vs 12 [25%]; p<0·0001), ≥10% (78 [78%] vs 5 [10%]; p<0·0001), and ≥15% (53 [53·0%] vs 2 [4·2%]; p<0·0001) in the semaglutide 2·4 mg group. Mean change in waist circumference was −11·9 cm (SE 0·7) with semaglutide versus −3·0 cm (1·0) with placebo (p<0·0001). Adverse events were reported by 90 (89%) of 101 participants in the semaglutide 2·4 mg
{"title":"Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial","authors":"Soo Lim, Supawan Buranapin, Xiaolei Bao, María Quiroga, Kyung Hee Park, Jee-Hyun Kang, Anders Rasmussen Rinnov, Arisara Suwanagool","doi":"10.1016/s2213-8587(25)00164-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00164-0","url":null,"abstract":"<h3>Background</h3>Consistent with WHO recommendations, obesity is defined as BMI ≥25 kg/m<sup>2</sup> in many Asian populations because of increased health risks at lower BMIs than in other populations. We aimed to investigate the efficacy and safety of once-weekly subcutaneous semaglutide 2·4 mg versus placebo in an Asian population with BMI ≥25 kg/m<sup>2</sup>, together with lifestyle interventions.<h3>Methods</h3>STEP 11 was a 44-week, randomised, double-blind, placebo-controlled, phase 3 trial conducted at 12 clinical sites in South Korea and Thailand. Adults (aged ≥18 years in Thailand and ≥19 years in South Korea) with obesity (BMI ≥25 kg/m<sup>2</sup>) of Asian descent, without diabetes, were randomly assigned 2:1 with a computer-generated sequence and block randomisation to once-weekly subcutaneous semaglutide 2·4 mg or placebo, with a reduced-calorie diet and increased physical activity. Participants, care providers, investigators, and assessors were masked to allocation. Coprimary endpoints, measured in all randomly assigned participants by intention to treat, were percentage bodyweight change and the proportion of participants reaching ≥5% bodyweight reduction. Confirmatory secondary endpoints were the proportion of participants with ≥10% and ≥15% bodyweight reductions and change in waist circumference. Safety was assessed via the assessment of adverse events in all participants who received at least one dose of semaglutide or placebo. This trial was registered at <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04998136</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>).<h3>Findings</h3>Between Aug 15, 2022, and Nov 20, 2023, 150 participants were randomly assigned (101 to semaglutide 2·4 mg and 49 to placebo). Six (6%) in the semaglutide group and two (4%) in the placebo group discontinued treatment before week 44. 111 (74%) were female and 39 (26%) male, with a mean age of 39 years (SD 11), mean bodyweight of 83·8 kg (18·1), and mean BMI of 31·3 kg/m<sup>2</sup> (5·2). At week 44, mean change in bodyweight was −16·0% (SE 0·7) in the semaglutide 2·4 mg group versus −3·1% (0·9) in the placebo group (p<0·0001), and a greater proportion of participants reached bodyweight reductions of ≥5% (96 [96%] <em>vs</em> 12 [25%]; p<0·0001), ≥10% (78 [78%] <em>vs</em> 5 [10%]; p<0·0001), and ≥15% (53 [53·0%] vs 2 [4·2%]; p<0·0001) in the semaglutide 2·4 mg group. Mean change in waist circumference was −11·9 cm (SE 0·7) with semaglutide versus −3·0 cm (1·0) with placebo (p<0·0001). Adverse events were reported by 90 (89%) of 101 participants in the semaglutide 2·4 mg","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"21 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-15DOI: 10.1016/s2213-8587(25)00201-3
Priya Sumithran, Louise A Baur
No Abstract
没有抽象的
{"title":"Growing evidence for semaglutide efficacy in Asian adults with obesity","authors":"Priya Sumithran, Louise A Baur","doi":"10.1016/s2213-8587(25)00201-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00201-3","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"72 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144857878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-12DOI: 10.1016/s2213-8587(25)00220-7
Jennifer Lynn Sherr, Laura M Nally
No Abstract
没有抽象的
{"title":"Continuous ketone monitoring for diabetes: a new era for diabetes","authors":"Jennifer Lynn Sherr, Laura M Nally","doi":"10.1016/s2213-8587(25)00220-7","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00220-7","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"95 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144825468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-11DOI: 10.1016/s2213-8587(25)00229-3
Eric Ravussin, Shengping Yang
No Abstract
没有抽象的
{"title":"Prevalence of clinical obesity in the All of Us cohort","authors":"Eric Ravussin, Shengping Yang","doi":"10.1016/s2213-8587(25)00229-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00229-3","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"22 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144819421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：